• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 22nd August 2017

An Update on the EQ-5D-5L Value Set for England

In this blog we (1) summarise the current status of the EQ-5D-5L value set for England; (2) highlight NICE’s recent statement on the values to be used in the reference case; (3) briefly explain why there are differences between the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

In this blog we (1) summarise the current status of the EQ-5D-5L value set for England; (2) highlight NICE’s recent statement on the values to be used in the reference case; (3) briefly explain why there are differences between the EQ-5D-3L and EQ-5D-5L; and (4) discuss why those differences might be important. We then (5) explain the next steps, including an independent quality assurance of the value set, and (6) provide an overview of current research projects underway at OHE to provide further evidence on the implications of new value sets for HTA and other uses.

In this blog we (1) summarise the current status of the EQ-5D-5L value set for England; (2) highlight NICE’s recent statement on the values to be used in the reference case; (3) briefly explain why there are differences between the EQ-5D-3L and EQ-5D-5L; and (4) discuss why those differences might be important. We then (5) explain the next steps, including an independent quality assurance of the value set, and (6) provide an overview of current research projects underway at OHE to provide further evidence on the implications of new value sets for HTA and other uses.

1. What is the current status of the EQ-5D-5L value set for England?

An English value set for the EQ-5D-5L, the new five-level version of the EuroQol Group’s EQ-5D instrument, is now available. This is the output of a research collaboration led by Professor Nancy Devlin of OHE and Professor Ben van Hout of the University of Sheffield’s School of Health and Related Research.

The value set study is reported in two papers, both now available open-access in Health Economics. The first paper summarises the methods used to elicit stated preferences from the general public, reports the value set produced from that work and compares it to the original EQ-5D-3L value set for the UK and the ‘crosswalk’ algorithm used to provide an interim means of valuing EQ-5D-5L data. The second paper provides details of the innovative methods used to model the stated preference data to produce the EQ-5D-5L value set.

Earlier version of both papers were released as OHE Research Papers in 2016. The purpose of the Research Paper versions was to make the work-in-progress publicly accessible and to stimulate discussion and critical comment. The Health Economics papers contain some changes in comparison to the earlier versions – these are the result of feedback received as part of the journal’s peer review process. However, the practical impact of the changes is small and the overall conclusions of the research remain the same.

​2. What is NICE’s current position on the EQ-5D-5L?

NICE recently released a position statement on the use of the EQ-5D-5L value set for England. Key elements are that:

  • the EQ-5D-3L value set continues to be used for reference case analyses;
  • where EQ-5D-5L data have been collected, reference case analyses should calculate utilities by mapping the EQ-5D-5L descriptive system data onto the EQ-5D-3L value set;
  • the mapping function developed by van Hout et al. (2012) should be used for reference case analyses of EQ-5D-5L data;
  • NICE supports sponsors of prospective clinical studies continuing to use the EQ-5D-5L to collect data on quality of life.

 3. What are the differences between the EQ-5D-5L and the EQ-5D-3L, and why might that be important?

There are two differences between the two questionnaires:

a) The way health is described is different. The EQ-5D-5L has five levels rather than three, and has improved the labels used for certain levels. For example, for the worst level of mobility problems, ‘Confined to bed’ in the EQ-5D-3L has been replaced by ‘Unable to walk about’ in the EQ-5D-5L.

b) The way health states values are derived is different. Value sets for the EQ-5D-5L around the world, including the value set for England, have been produced using an international protocol developed by the EuroQol Group. The methods used to collect and model preference data are different from those that were used to generate the EQ-5D-3L value set. Differences in values might also be expected because the Measurement and Valuation of Health (MVH) study underpinning the EQ-5D-3L value set was conducted over two decades ago.

The overall difference between the EQ-5D-5L and the EQ-5D-3L will be a product of differences in both description and valuation. 

OHE has previously reported on the important differences that exist between the UK EQ-5D-3L value set and the new EQ-5D-5L value set for England (Mulhern et al, 2017).

4. What will happen next?

NICE says that it intends to review its position in August 2018. 

In line with the Macpherson report recommendations on quality assurance of modelling work affecting government policy, the English Department of Health will commission an independent quality assurance of the methods used to create the EQ-5D-5L value set for England.

Speaking on behalf of the value set for England study team, OHE’s Professor Devlin comments, “Given the importance of the EQ-5D-5L value set for health technology appraisal in England and elsewhere, we expected from the outset that the new EQ-5D-5L value set would be subject to close scrutiny. We have prepared our data and code for sharing to facilitate the independent quality assurance required by the government.”

Professor Devlin also adds, “Value set studies inevitably involve decisions about how to handle the data and what assumptions to use in modelling. Our project was overseen by a steering group comprising Department of Health senior economists, senior representatives from NICE and academic health economists. All aspects of the data and modelling were reported to the steering group members at regular meetings, and their guidance was sought on the modelling approaches we used.”

5. What further research is OHE doing?

A range of other research projects are also either planned or underway, both in the UK and internationally, commissioned by NICE, the EuroQol Group and other organisations, to better understand the differences between the EQ-5D-3L and the EQ-5D-5L.

These include the following studies underway at OHE:

  • Comparing the EQ-5D-3L and EQ-5D-5L in a cohort of cancer patients – a collaboration between OHE, Curtin University and King’s College London.
  • A study being led by OHE to re-model the original EQ-5D-3L UK valuation data using the innovative modelling methods used in the EQ-5D-5L value set study in England – preliminary results from that study will be presented at the EuroQol Scientific Plenary Meeting in September.
  • Comparing the EQ-5D-3L and EQ-5D-5L in a cohort of diabetes patients, in collaboration with the Centre for Health Economics Research and Evaluation, University of Technology Sydney.
  • Cost utility analyses using EQ-5D: does how the utility values are derived matter? A collaboration between OHE and the National University of Singapore.

The EuroQol Research Foundation has established a 3L/5L Taskforce (co-chaired by Professors John Brazier and Nancy Devlin) to coordinate a number of other research projects to better understand the differences between the EQ-5D-3L and EQ-5D-5L descriptive systems and values sets and the implications for users. 

Both of the Health Economics papers are now available open access:

Devlin, N., Shah, K., Feng, Y., Mulhern, B. and van Hout, B., 2017. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics. DOI: 10.1002/hec.3564

Feng, Y., Devlin, N., Shah, K., Mulhern, B. and van Hout, B., 2017. New methods for modelling EQ-5D-5L value sets: An application to English data. Health Economics. DOI: 10.1002/hec.3560

For more information, please contact Nancy Devlin.

Syntax files available to download here.

The syntax is based on the value set reported in Appendix II of Devlin et al. (2017). The 5L indices calculated are identical to the results that use the central estimates reported in Table II.

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • News Releases

Related News

  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
  • News
  • October 2021

We have launched OHE Bulletin, a new monthly newsletter

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!